BioStem Technologies (BioStem Technologies) Debt-to-Equity : -1.71 (As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

What is BioStem Technologies Debt-to-Equity?

BioStem Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $4.61 Mil. BioStem Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.41 Mil. BioStem Technologies's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-3.53 Mil. BioStem Technologies's debt to equity for the quarter that ended in Sep. 2023 was -1.71.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioStem Technologies's Debt-to-Equity or its related term are showing as below:

BSEM' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.23 Med: -0.89 Max: 12.5
Current: -1.71

During the past 13 years, the highest Debt-to-Equity Ratio of BioStem Technologies was 12.50. The lowest was -3.23. And the median was -0.89.

BSEM's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs BSEM: -1.71

BioStem Technologies Debt-to-Equity Historical Data

The historical data trend for BioStem Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioStem Technologies Debt-to-Equity Chart

BioStem Technologies Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-3.23

-1.25

-0.97

-0.81

-1.25

BioStem Technologies Quarterly Data
	Sep15	Dec15	Dec16	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Dec21	Mar22	Sep22	Dec22	Mar23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	N/A	-1.25	-1.10	-1.71

Competitive Comparison of BioStem Technologies's Debt-to-Equity

For the Biotechnology subindustry, BioStem Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioStem Technologies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Debt-to-Equity falls into.

BioStem Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioStem Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.051	+	1.038)	/	-4.076
	=	-1.25

BioStem Technologies's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.613	+	1.41)	/	-3.526
	=	-1.71

BioStem Technologies (OTCPK:BSEM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BioStem Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioStem Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioStem Technologies (BioStem Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioStem Technologies Inc (OTCPK:BSEM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2836 Center Port Circle, Pompano Beach, FL, USA, 33064

Website

https://www.biostemtechnologies.com

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include RHEO, AEON, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.